TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.

Sudeep Pushpakom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.